Generic entry timeline

TRIHEPTANOIN generics — when can they launch?

TRIHEPTANOIN (TRIHEPTANOIN) · · 2 active US patents · 0 expired

Earliest patent expiry
2029-04-28
3 years remaining
Full patent estate to
2034-11-14
complete protection through 2034
FDA approval
2020

Where TRIHEPTANOIN sits in the generic timeline

Imminent generic cliff: earliest active US patent for TRIHEPTANOIN expires in 2029 (~3 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.

Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.

Patent estate by type — active patents

Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.

  • Formulation — 2 patents

Sample patent estate

Showing 2 of 2 active US patents. View full estate on the TRIHEPTANOIN drug page →

  • US8697748 Formulation · expires 2029-04-28
    This patent protects a method for treating glycogen storage disease using a composition containing ketogenic odd carbon fatty acids.
    USPTO title: Glycogen or polysaccharide storage disease treatment method
  • US12551461 Formulation · expires 2034-11-14
    This patent protects solid compositions of triglycerides with one or more fatty acids, such as triheptanoin, and their therapeutic uses.
    USPTO title: Compositions of triglycerides and uses thereof

Sources

Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.

Get generic entry alerts

Free Pharma CI alerts on TRIHEPTANOIN — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.

Subscribe free →